Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
follow us on youtube
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Site Search
toggle main menu
News
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/16/2015
Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures
12/07/2015
Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting
12/03/2015
Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise
11/19/2015
Marinus's Ganaxolone to be Featured in Two Poster Presentations at the 69th Annual Meeting of the American Epilepsy Society
11/12/2015
Marinus Pharmaceuticals to Present at Stifel Healthcare Conference
11/10/2015
Marinus Pharmaceuticals to Present At Credit Suisse Healthcare Conference
11/06/2015
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11/05/2015
Marinus Pharmaceuticals Announces Public Offering of Common Stock
10/29/2015
Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation
10/29/2015
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
10/26/2015
Marinus Announces Key Initial Observations From Study in PCDH19 Female Pediatric Epilepsy
09/09/2015
Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures
08/04/2015
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2015 Financial Results
07/06/2015
Published Data Support Scientific Basis for Ganaxolone Use in PCDH19 Female Epilepsy
06/16/2015
Marinus Pharmaceuticals to Present at JMP Securities Life Sciences Conference
05/18/2015
Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference
03/27/2015
MRNS - PCDH19 Female Pediatric Epilepsy Featured on CBS Philly
03/25/2015
Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy
03/16/2015
Marinus Pharmaceuticals to Participate in Future Leaders in the Biotech Industry Conference
02/09/2015
Marinus Pharmaceuticals to Participate in Leerink Global Healthcare Conference
02/03/2015
Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy
02/02/2015
Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference
01/27/2015
Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day